Cargando…

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study

Detalles Bibliográficos
Autores principales:	Candelaria, Myrna, Cetina, Lucely, Garcia, Alicia, Wegman-Ostrosky, Talia, Robles, Elizabeth, González-Fierro, Aurora, López-Graniel, Carlos, González, Aaron, Cantú, David, Ribera, Lesbia, Taja-Chayeb, Lucia, Trejo-Becerril, Catalina, Pérez-Cárdenas, Enrique, Pérez-Plasencia, Carlos, Chavez-Blanco, Alma, Dueñas-González, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1796572/ http://dx.doi.org/10.1186/1471-2407-7-S1-A28

Ejemplares similares

Chemoradiation with cisplatin followed by either brachytherapy or radical hysterectomy. A non-randomized comparison in FIGO stages IB2-IIA
por: Cetina, Lucely, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study
por: Chavez-Blanco, Alma, et al.
Publicado: (2005)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results
por: Cetina, Lucely, et al.
Publicado: (2006)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma
por: Candelaria, Myrna, et al.
Publicado: (2006)

Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients
por: Cetina, Lucely, et al.
Publicado: (2009)

Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer
por: Lopez-Graniel, Carlos, et al.
Publicado: (2005)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Radiation-sparing managements for cervical cancer: a developing countries perspective
por: Candelaria, Myrna, et al.
Publicado: (2006)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

Response to Hydralazine-Valproate in a Patient with Mycosis Fungoides
por: Dueñas-Gonzalez, Alfonso, et al.
Publicado: (2010)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Epigenetics of cervical cancer. An overview and therapeutic perspectives
por: Dueñas-González, Alfonso, et al.
Publicado: (2005)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer
por: Kuroda, Yuuki, et al.
Publicado: (2012)

ctDNA Is Useful to Detect Mutations at Codon 641 of Exon 16 of EZH2, a Biomarker for Relapse in Patients with Diffuse Large B-Cell Lymphoma
por: Díaz-Chávez, José, et al.
Publicado: (2022)

Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients
por: Mabuchi, Seiji, et al.
Publicado: (2017)

Escalated radiation and prophylactic extended field nodal irradiation are beneficial for FIGO IIIB cervical cancer patients’ prognosis
por: Meng, Qingyu, et al.
Publicado: (2018)

Serous adenocarcinoma of the fallopian tube, associated with verrocous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors
por: Cantu de Leon, David, et al.
Publicado: (2009)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Vulvar fibroadenoma: a common neoplasm in an uncommon site
por: Cantú de Leon, David, et al.
Publicado: (2009)

New molecular targets against cervical cancer
por: Duenas-Gonzalez, Alfonso, et al.
Publicado: (2014)

Hydralazine-Induced Vasculitis
por: Gandhi, Pulkit, et al.
Publicado: (2023)

Primary Malignant Melanoma of the Uterine Cervix Treated with Ultraradical Surgery: A Case Report
por: Calderón-Salazar, Luz, et al.
Publicado: (2011)

Evaluation of the efficacy of prophylactic extended field irradiation in the concomitant chemoradiotherapy treatment of locally advanced cervical cancer, stage IIIB in the 2018 FIGO classification
por: Meng, Qingyu, et al.
Publicado: (2019)

Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
por: Perez-Plasencia, Carlos, et al.
Publicado: (2006)

Strategies for the evaluation of DNA damage and repair mechanisms in cancer
por: Figueroa-González, Gabriela, et al.
Publicado: (2017)

Hydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
por: Zuckerman, Roman, et al.
Publicado: (2018)

Molecular characterization of BRCA1 and BRCA2 genes in breast cancer patients under 40 years-old or with familiar cancer history
por: Millan, Silvia Vidal, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_se6a0ct9u4ue2ppsblttnaght3